3 Biotech Stocks Wall Street Analysts Are Bullish on for 2026

Key Takeaways EyePoint's late-stage retinal programs and upcoming data readouts position it for momentum beyond 2025.ANI Pharmaceuticals' rare disease franchise is scaling fast, led by surging Cortrophin Gel sales.Tango Therapeutics is advancing precision oncology with promising PRMT5 inhibitorsThe biotech sector has put up a strong recovery in 2025. The Nasdaq Biotechnology Index has risen 33.1% so far this year. The index bottomed out in April 2025 on potential imposition of steep tariffs, which weighed h ...